Formulation Development
Nemera & Nelson Labs Europe Strengthen Partnership to Offer Integrated Services to Customers
This strategic alliance will give a unique advantage to pharmaceutical & bio-tech customers – accelerating the go-to-market of their drug-device combination products by offering analytical chemistry, drug compatibility lab testing and expert advice….
Ajinomoto Bio-Pharma Services Awarded Three CDMO Leadership Awards
Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, received three CDMO Leadership Awards in the categories Capabilities, Compatibility, and Expertise…
Immutep Announces Initiation of Phase 2/3 Trial for Eftilagimod Alpha Plus Paclitaxel in Metastatic Breast Cancer
Immutep Limited recently announced the initiation of AIPAC-003 (Active Immunotherapy, Eftilagimod Alpha, and PAClitaxel), an integrated Phase 2/3 trial to evaluate eftilagimod alpha (efti) in combination…
Proteovant Therapeutics to Present Preclinical Data From Estrogen Receptor & IKZF2 Protein Degrader Programs
Proteovant Therapeutics, a Roivant Sciences (Nasdaq: ROIV) company leveraging the process of protein degradation to discover and develop transformative medicines for the treatment of patients…
Pii Announces New Vice President of Sales
Pharmaceutics International, Inc. (Pii) recently announced John Phillips has joined the company as Vice President of Sales. Mr. Phillips brings a wealth of almost 30…
WHITEPAPER - Improve Process Economics & Enable High Protein Concentrations
What if you could achieve higher protein concentrations during downstream processing? This whitepaper spotlights how excipient combinations can enhance manufacturability and final concentration of mAb formulations.
Cingulate & Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate
Cingulate Inc. and Indegene recently announced a joint commercialization agreement to provide commercial support for Cingulate’s lead candidate CTx-1301 (dexmethylphenidate), a novel, investigational treatment….
Atavistik Bio Announces Publication Describing Foundational Technology for its AMPS Platform
Atavistik Bio recently announced a new publication in the journal Science by Atavistik Bio co-founder Jared Rutter, PhD, describing the foundational technology upon which the…
WEBINAR - Step Into the Future of Therapeutic Antibody Discovery
Join us to hear about our new biotherapeutic antibody discovery service — the Pioneer Platform, and how it can help you find your next lead candidate.
First Wave BioPharma Announces First Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation
First Wave BioPharma, Inc. recently announced that the first patient was dosed in the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation of….
Catalent Expands UpTempo AAV Platform to Accelerate Development of Gene Therapies
Catalent recently announced the expansion of its UpTempo platform process for the development and CGMP manufacturing of adeno-associated viral (AAV) vectors. The platform now includes an…
Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib
Sermonix Pharmaceuticals Inc. and Guardant Health, Inc. recently announced the initiation of a registrational Phase 3 clinical study comparing targeted lasofoxifene in combination with the…
Ribon Therapeutics Doses First Patient in Phase 1 Clinical Study for Patients With Moderate-to-Severe Atopic Dermatitis
Ribon Therapeutics recently announced dosing the first patient in the open-label cohort of patients with moderate-to-severe atopic dermatitis to measure the pharmacodynamic activity of RBN-3143…
QSAM Biosciences Receives FDA Clearance to Expand Enrollment Criteria in its Phase 1 Study Targeting Metastatic Bone Cancer
QSAM Biosciences Inc. recently announced US FDA has cleared the Company’s amended clinical trial protocol increasing the maximum age of participants to 75 years old…
Lonza Upgrades Powder Characterization Capabilities at Tampa Site
Lonza recently announced a significant enhancement to its powder characterization capabilities at its Small Molecules site in Tampa, FL. The facility has been upgraded to…
Evonik Opens New Facility for Pharmaceutical Lipids at Site in Germany
Evonik is opening a new GMP facility to manufacture lipids for advanced, pharmaceutical drug delivery applications. The lipid launch facility is located at the company’s site in Hanau, Germany and….
Indaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients With Advanced Solid Tumors
Indaptus Therapeutics, Inc. recently announced the dosing of the first subject in INDP-D101, the company’s first-in-human, open label, dose escalation and expansion, multicenter Phase 1…
BioStem Technologies to Acquire Majority of Assets of Auxocell Laboratories, Inc.
BioStem Technologies Inc. recently announced it has entered into an agreement to acquire the majority of the assets of Auxocell Laboratories, Inc., a leading solid tissue processing equipment manufacturer…..
Certara Announces Release of Simcyp PBPK Simulator Version 22, Expanding Ability to Simulate Untested Scenarios for New Patient & Therapeutic Types
Certara, Inc. recently announced the release of Simcyp Simulator Version 22, which includes new capabilities and updated features to the company’s population-based modeling and simulation…
Dyadic Provides Phase 1 Clinical Trial Update for its COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
Dyadic International, Inc. recently provided an update regarding its Phase 1 Clinical Trial for its DYAI-100 COVID-19 recombinant protein receptor binding domain (RBD) booster vaccine…
